Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

A Fojo

Showing results (11-20 of 20) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 20 results.
Science (New York, N.Y.)|May 2, 1986
Human multidrug-resistant cell lines: increased mdr1 expression can precede gene amplificationD W Shen, A Fojo, J E Chin, et al.
Molecular and Cellular Biology|November 1, 1986
Multidrug resistance of DNA-mediated transformants is linked to transfer of the human mdr1 geneD W Shen, A Fojo, I B Roninson, et al.
Somatic Cell and Molecular Genetics|July 1, 1986
Localization of multidrug resistance-associated DNA sequences to human chromosome 7A Fojo, R Lebo, N Shimizu, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 31, 2000
Role of a doxorubicin-containing regimen in relapsed and resistant lymphomas: an 8-year follow-up study of EPOCHM Gutierrez, B A Chabner, D Pearson, et al.
Journal of the National Cancer Institute|January 18, 1989
Expression of a multidrug resistance gene in human cancersL J Goldstein, H Galski, A Fojo, et al.
Proceedings of the National Academy of Sciences of the United States of America|June 1, 1986
Isolation of human mdr DNA sequences amplified in multidrug-resistant KB carcinoma cellsI B Roninson, J E Chin, K G Choi, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 1, 1995
Controlled trial of dexverapamil, a modulator of multidrug resistance, in lymphomas refractory to EPOCH chemotherapyW H Wilson, S E Bates, A Fojo, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 1, 1994
Paclitaxel in doxorubicin-refractory or mitoxantrone-refractory breast cancer: a phase I/II trial of 96-hour infusionW H Wilson, S L Berg, G Bryant, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 1, 1995
Phase II study of paclitaxel in relapsed non-Hodgkin's lymphomasW H Wilson, B A Chabner, G Bryant, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 1, 1993
EPOCH chemotherapy: toxicity and efficacy in relapsed and refractory non-Hodgkin's lymphomaW H Wilson, G Bryant, S Bates, et al.
Pageof 2

Showing results (11-20 of 20) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 20 results.
Science (New York, N.Y.)|May 2, 1986
Human multidrug-resistant cell lines: increased mdr1 expression can precede gene amplificationD W Shen, A Fojo, J E Chin, et al.
Molecular and Cellular Biology|November 1, 1986
Multidrug resistance of DNA-mediated transformants is linked to transfer of the human mdr1 geneD W Shen, A Fojo, I B Roninson, et al.
Somatic Cell and Molecular Genetics|July 1, 1986
Localization of multidrug resistance-associated DNA sequences to human chromosome 7A Fojo, R Lebo, N Shimizu, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 31, 2000
Role of a doxorubicin-containing regimen in relapsed and resistant lymphomas: an 8-year follow-up study of EPOCHM Gutierrez, B A Chabner, D Pearson, et al.
Journal of the National Cancer Institute|January 18, 1989
Expression of a multidrug resistance gene in human cancersL J Goldstein, H Galski, A Fojo, et al.
Proceedings of the National Academy of Sciences of the United States of America|June 1, 1986
Isolation of human mdr DNA sequences amplified in multidrug-resistant KB carcinoma cellsI B Roninson, J E Chin, K G Choi, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 1, 1995
Controlled trial of dexverapamil, a modulator of multidrug resistance, in lymphomas refractory to EPOCH chemotherapyW H Wilson, S E Bates, A Fojo, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 1, 1994
Paclitaxel in doxorubicin-refractory or mitoxantrone-refractory breast cancer: a phase I/II trial of 96-hour infusionW H Wilson, S L Berg, G Bryant, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 1, 1995
Phase II study of paclitaxel in relapsed non-Hodgkin's lymphomasW H Wilson, B A Chabner, G Bryant, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 1, 1993
EPOCH chemotherapy: toxicity and efficacy in relapsed and refractory non-Hodgkin's lymphomaW H Wilson, G Bryant, S Bates, et al.
Pageof 2